| Similar Articles |
|---|
 |
Nursing
June 2010
Daniel A. Hussar |
New drugs 2010, part 2 In this article, you'll learn about 14 recently marketed new drugs.   |
Nursing
February 2010
Daniel A. Hussar |
New Drugs 2010, PART 1 In this article, you'll learn about 16 new drugs. |
Nursing
June 2011
Daniel A. Hussar |
New Drugs 2011: Part 2 In this article, you'll learn about seven recently approved drugs, including: fingolimod hydrochloride, an oral drug indicated to treat patients with relapsing forms of multiple sclerosis. |
Nurse Practitioner
February 2011
Jennifer M. Belavic |
Annual Drug Update: 2010 in Review In 2010, the FDA approved several new drugs and new indications for use in primary care. From new therapies for adults with rheumatoid arthritis to a combination drug for benign prostatic hyperplasia, NPs need to be aware of the latest medications now available. |
Nursing
March 2012
Daniel A. Hussar |
New Drugs 2012: part I In this article, you'll learn about 11 recently approved drugs. |
Nurse Practitioner
February 2012
Jennifer M. Belavic |
Annual drug update 2011 in review Many new medications were approved throughout 2011. This article will cover a variety of drugs that will be useful in nurse practitioner practice |
American Journal of Nursing
May 2010
Corbridge & Corbridge |
Asthma in Adolescents and Adults This article outlines current guideline recommendations for asthma and reviews what clinicians need to teach patients about its pathophysiology, pharmacotherapy, self monitoring, and environmental control. |
Nursing
May 2012
Tim Blake |
Three Medication Pathways for Bipolar Disorder No matter where you work, you're likely to care for patients with bipolar disorder, which affects about 2.6% of people age 18 and older per year. |
Nurse Practitioner
September 2010
Moloney & Cranwell-Bruce |
Pharmacological Management of Migraine Headaches Migraine is one of the top 20 causes of disability worldwide, occurring in 17.6% of women and 5.7% of men |
Nurse Practitioner
July 2010
Kristine A. Scordo |
Treating antiretroviral-induced dyslipidemia in HIV-infected adults Studies indicate that HIV-infected patients (both males and females) may be at an increased risk for the development of cardiovascular disease |
Nursing
January 2011
Carl A. Kirton |
HIV: The Changing Epidemic Since its emergence in the early 1980s, HIV infection in the United States has evolved from an acute debilitating condition to a chronic, treatable illness. |
American Family Physician
August 1, 2003
Meyer et al. |
Sudden Arrhythmia Death Syndrome: Importance of the Long QT Syndrome In approximately 5 percent of sudden cardiac deaths, no demonstrable anatomic abnormality is found. Some cases are caused by sudden arrhythmia death syndrome. A prolonged QT interval is a common thread among the various entities associated with sudden arrhythmia death syndrome. |
Nursing
March 2011
Ali & Gray-Vickrey |
Limiting the Damage From Acute Kidney Injury This article will discuss your role in early detection and management of AKI with an emphasis on care for older adults. |
The Motley Fool
November 29, 2010
Brian Orelli |
Head to Head: Merck vs. Itself Merck's HIV drug doesn't work as well when taken once daily. |
Nursing
February 2012
Pezzotti & Freuler |
Using anticoagulants to steer clear of clots This article will review coagulation and provide important information about several commonly used anticoagulants and their reversal agents. |
The Motley Fool
December 15, 2010
Brian Orelli |
Beautiful Efficacy, Wrong Pill Lexicon Pharmaceuticals presented beautiful data showing a pill it gave rheumatoid arthritis patients decreased symptoms in 49% of patients. Unfortunately, the pill was a dummy pill with no active ingredient. |
Nursing
September 2010
Margaret M. Bolton |
Sounding the alarm about metabolic syndrome Any health problem that affects a third of American adults is sure to impact your nursing practice. Metabolic syndrome, a growing and commonly silent condition, poses a significant public health crisis. |
Nurse Practitioner
August 2011
Davis et al. |
Supportive approaches for Alzheimer Disease Alzheimer disease accounts for almost 80% of all dementia diagnoses. Currently, more than 5 million Americans suffer from this debilitating illness, with the highest prevalence in the oldest age groups. |
The Motley Fool
August 30, 2010
Brian Orelli |
Maybe Not a Blockbuster, But We'll Take It Novartis' newest addition, blood pressure medication Tekamlo, isn't going to rocket to the top of the 2020 best seller list, but it's still a nice addition nonetheless. |
The Motley Fool
September 7, 2010
Luke Timmerman |
Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too. |
The Motley Fool
August 10, 2010
Ryan McBride |
Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive. |
Nurse Practitioner
December 2011 |
Managing pain in obese patients Obesity-related pain conditions can limit the patient's efforts at increasing activity and limit quality of life. This article will offer information on these conditions and treatment options. |
American Journal of Nursing
November 2011
Christine L. Cutugno |
The 'Graying' of Trauma Care: Addressing Traumatic Injury in Older Adults Evidence-based strategies for managing trauma and its complications in this population. |
The Motley Fool
September 14, 2010
Luke Timmerman |
Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug. |
Nursing
January 2012
Crawford & Harris |
Fluid and Electrolyte Series Balancing act Calcium & phosphorus In this article, we review the roles of calcium and phosphorus, including assessment points and nursing considerations for patients experiencing imbalances of these important electrolytes. |
The Motley Fool
September 8, 2010
Brian Orelli |
You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win. |
Pharmaceutical Executive
November 1, 2012
Sue Barrowcliffe |
Real World Insights Commercial teams as well as patients can benefit from managed access programs, which are designed to provide access to medicines outside of the clinical and commercial setting, for patients who have no other available treatment options. |
American Journal of Nursing
September 2011
Adams & Tolich |
Original Research: Blood Transfusion: The Patient's Experience This study therefore sought to identify how well patients understand the role of blood transfusion in their treatment and whether it causes them discomfort. |
The Motley Fool
June 6, 2011
Luke Timmerman |
Exelixis Zeroes In on Lead Drug, Sees Activity in the Bones of Prostate Cancer Patients Is Exelixis' risky bet about to pay off? |
The Motley Fool
February 24, 2011
Brian Orelli |
Profit From Personalized Medicine Pfizer's drug works well, but consider these companies instead. |
Pharmaceutical Executive
December 1, 2013
Vansgaard et al. |
Develop Drugs for People, Not Just Bodies A patient-centric approach to drug development delivers the benefits that actually create value |
The Motley Fool
March 31, 2011
Brian Orelli |
Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones? |
Chemistry World
June 14, 2012
Andrew Turley |
Good signs for Merck & Co insomnia pill In Phase III trials, insomnia drug candidate suvorexant performed well, reducing the time patients needed to fall asleep and increasing the total time sleeping, with some patients benefitting from the very first night of treatment. |
The Motley Fool
July 8, 2011
Luke Timmerman |
Amylin, Alkermes Once-Weekly Diabetes Drug Passes Heart Trial What does this mean for the drug companies? |
Pharmaceutical Executive
August 1, 2011
Jennifer Ringler |
The Adherence Fight: A TKO? Why does the match against medicines compliance always seem to end in an easy knockout? |
Pharmaceutical Executive
June 1, 2014
Ben Comer |
Take as Directed: From Force to Finesse in Promoting Adherence Healthcare players tout patient education and engagement as the keys to better drug adherence rates. Patients agree, as long as that translates to convenient and affordable access to therapy. |
Pharmaceutical Executive
November 1, 2012
Lauri Mitchell |
Who Pays for Specialty Medicines? Providers and patients fish for that delicate balance between access and abandonment. |
The Motley Fool
March 25, 2011
Brian Orelli |
Pfile Pfizer Under "Potential" Researchers reported promising finding from a clinical trial of Pfizer's new drug, CP-870,893, in pancreatic cancer patients in the most recent issue of the journal Science. |
